

# Open Research Online

---

The Open University's repository of research publications and other research outputs

## LncRNA *HORAS5* promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism

### Journal Item

#### How to cite:

Pucci, Perla; Venalainen, Erik; Alborelli, Ilaria; Quagliata, Luca; Hawkes, Cheryl; Mather, Rebecca; Romero, Ignacio A; Rigas, Sushila; Wang, Yuzhuo and Crea, Francesco (2020). LncRNA HORAS5 promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. *Epigenomics*, 12(13) pp. 1123–1138.

For guidance on citations see [FAQs](#).

© 2020 Future Medicine Ltd



<https://creativecommons.org/licenses/by-nc-nd/4.0/>

Version: Accepted Manuscript

Link(s) to article on publisher's website:

<http://dx.doi.org/doi:10.2217/epi-2019-0316>

---

Copyright and Moral Rights for the articles on this site are retained by the individual authors and/or other copyright owners. For more information on Open Research Online's data [policy](#) on reuse of materials please consult the policies page.

---

[oro.open.ac.uk](http://oro.open.ac.uk)

*First draft submitted: 22 October 2019; Accepted for publication: 07 April 2020; Published online: TBC*

## **LncRNA *HORAS5* promotes taxane resistance in castration resistant prostate cancer via a *BCL2A1*-dependent mechanism**

### **Abstract**

**Background:** Castration resistant prostate cancer (CRPC) is an incurable malignancy. Long non-coding RNAs (lncRNAs) play key roles in drug resistance.

**Materials & Methods:** LncRNA *HORAS5* role in cabazitaxel resistance (i.e. cell-count, IC<sub>50</sub> and caspase activity) was studied via lentiviral-mediated overexpression and siRNA-based knock-down (KD). Genes expression was analysed with RNA-sequencing, RT-qPCR and western-blot. *HORAS5* expression was queried in clinical database.

**Results:** Cabazitaxel increased *HORAS5* expression that upregulated *BCL2A1*, thereby protecting CRPC cells from cabazitaxel-induced apoptosis. *BCL2A1* KD decreased cell-count and increased apoptosis in CRPC cells. *HORAS5*-targeting antisense oligonucleotide (ASO) decreased cabazitaxel IC<sub>50</sub>. In CRPC clinical samples, *HORAS5* expression increased upon taxane treatment.

**Conclusion:** *HORAS5* stimulates the expression of *BCL2A1* thereby decreasing apoptosis and enhancing cabazitaxel resistance in CRPC cells.

**Keywords:** Drug resistance, *HORAS5*, lncRNA, Castration resistant prostate cancer, *BCL2A1*.

## Introduction

Castration resistant prostate cancer (CRPC) is an incurable malignancy [1]. It occurs when prostate cancer (PCa) cells acquire mutations and other genetic and epigenetic alterations in the AR signalling and in cell survival pathways; hence they stop responding to androgen deprivation therapies [2–4]. At this stage, next generation hormonal treatments such as enzalutamide and abiraterone and chemotherapy such as docetaxel and cabazitaxel are the only effective treatment options [5–8]. In advanced CRPC stages, normally characterized by high metastatic burden (mCRPC), cancer cells can become resistant to these treatments. At this stage mCRPC patients median survival is very poor (1-2 years) [4], therefore novel therapeutic approaches to increase drug efficacy are urgently needed.

Long non-coding RNAs (lncRNAs) are >200bp transcripts that lack of protein-coding capacity and the majority are still uncharacterized [9]. Due to their ability to fold into various structures [10], they could have several functions and mechanisms of action inside the cells, some of which were recently described [11–14]. LncRNAs have been investigated in health and disease and some of them were characterized as key players in cancer-associated pathways such as development of metastatic status and drug resistance [15–19]. In the context of drug response, some studies showed that lncRNAs can increase drug sensitivity in specific cancers. However, several lncRNAs have been shown to promote resistance to various agents, such as hormonal therapy or chemotherapy agents [13,17,20,21].

In a recently published study, we have characterized the lncRNA *HORAS5* (i.e. *linc00161*) in PCa, showing that it was upregulated in patient derived xenografts (PDXs) models and increased the survival of AR<sup>+</sup> CRPC cells [22]. *HORAS5* was already studied in osteosarcoma cells where it showed a pro-apoptotic oncosuppressive role that determined the increase of cisplatin sensitivity via *miR-645* inhibition and action in the IFIT2 pathway [13]. Despite this evidence, *HORAS5* was then found to increase migration and invasion in hepatocellular carcinoma patients and higher expression of this transcript correlated with poor prognosis [23]. A recent study also showed that *HORAS5* can promote drug resistance in ovarian cancer via acting as a competing endogenous RNA (ceRNA) with another miRNA in a different pathway (*linc00161-miR-128-MAPK1* axis) [21]. All this evidence shows that *HORAS5* modulates drug-associated response in different malignancies and that this transcript can have different functions in different tissues.

Based on this evidence, we have decided to investigate whether *HORAS5* plays a role in the drug response of AR<sup>-</sup> and AR<sup>+</sup> CRPC cells. For this purpose, we have tested a panel of clinically relevant drugs on CRPC cells expressing different levels of this transcript [22]. We have shown that cabazitaxel was the only drug tested which induced a significant, concentration-dependent increase in *HORAS5* expression. Hence, we have decided to further investigate the role of *HORAS5* in cabazitaxel response. Our results suggest that *HORAS5* activates a BCL2A1-dependent mechanism of action, thereby inducing cabazitaxel resistance in CRPC cells.

## **Materials and Methods**

### **Cell culture**

Human PCa LNCaP, DU145 and 22rv1 cell lines were purchased from the American Type Culture Collection (ATCC, Burlington, ON, Canada). In particular, we have selected LNCaP cells, which express a mutated *AR* gene and grow in castrate testosterone concentrations [24] and in DU145 cells, which are *AR*<sup>-</sup> and a model of anaplastic CRPC [25,26]. LNCaP cells were cultured in RPMI-1640 ATCC modification from GIBCO (cat# A1049101) and DU145 and 22rv1 cells (DU145-NC, DU145-OE, 22rv1-NC and 22rv1-OE; see below and in suppl. fig. 4) in RPMI-1640 from GIBCO (cat# 21875034), supplemented with 10% of FBS and 1% antibiotics (penicillin and streptomycin). ATCC protocols were followed for culture passage and cells storage. Cells were cultured at 37°C in a 5% CO<sub>2</sub> humidified incubator.

### ***HORAS5* overexpression with lentiviral stable transduction**

DU145 cells that express *HORAS5* at undetectable levels were stably transfected with a lentivirus-derived particle that induced *HORAS5* overexpression (Genecopoeia, Cat# LPP-GS266B-Lv105-050).  $7.0 \times 10^4$  *AR*<sup>-</sup> Du145 and *AR*<sup>+</sup> 22rv1 cells were first seeded in 24-well plates and were incubated overnight. The following day, old media was replaced by media supplemented with polybrene (aka Hexadimethrine Bromide, Sigma Aldrich, Gillingham, UK, Cat# H9268) at a final concentration of 8 µg/mL to increase transduction efficiency [27]. After, 5 µL of the purified human *linc00161* (*HORAS5*) lentiviral particles (Titer:  $1.37 \times 10^8$  TU/mL where 1TU=100 copies of viral genomic RNA) were added to the wells and incubated overnight. The following day, the wells were washed with RPMI-1640 containing 10% FBS three times and were subsequently left for two days to reach confluence. 48h to 72h post-transduction, cells were split one-in-two into 6-well plates and were allowed to adhere for 5-6 hrs prior to antibiotic selection using puromycin (Gibco, Cat# A1113803). Selection lasted for two-weeks with media change every 3-4 days. To achieve high copy number, 3 µg/mL puromycin was selected. These cells were called Du145-OE and 22rv1-OE respectively and were passaged and frozen for long-term storage in liquid nitrogen. All overexpression experiments were normalized to cells transduced with the empty vector (DU145-NC and 22rv1-NC respectively) as lentiviral vectors did not induce phenotypic changes.

### **Total and subcellular-fractionated RNA extraction**

Total RNA was extracted using the RNeasy plus mini Kit (Qiagen, Manchester, UK) from cultured cells according to the manufacturer's protocol.

Nuclear- and cytoplasmic-fractionated RNA extraction was performed on cultured cells using the PARIS™ kit (Ambion, Loughborough, UK) following the manufacturer's protocol. DNase digestion

of the fractionated RNA was performed using the TURBO DNA-free™ Kit (Ambion, Loughborough, UK, Cat# AM1907).

### **Reverse-transcription and quantitative PCR (qPCR)**

Upon extraction, 1 µg of total RNA was reverse-transcribed using high capacity cDNA reverse transcription kit (Applied Biosystems, Loughborough, UK) following the kit instructions. The cDNA obtained was diluted 10 times prior the qPCR. TaqMan assays (Applied Biosystems, Loughborough, UK) were used for the qPCR to assess gene expression as per the manufacturer's protocol. The TaqMan assays used were *LINC00161* (Hs00863167\_g1) and *BCL2A1* (Hs00187845\_m1). *HPRT1* (Hs02800695\_m1) was used as housekeeping control in all the RT-qPCR experiments. For subcellular localisation RT-qPCR experiments, the probes *MALAT1* (Hs00273907\_s1) and *GAPDH* (Hs02786624\_g1) were also used as nuclear and cytoplasmic control respectively.

### **siRNA-mediated gene knockdown**

Gene knockdown (KD) experiments were performed using the reverse transfection method (Hattori et al., 2017). Cells were seeded in 6-well or 96-well plates with the lipid:siRNA mixture prepared using the RNAiMAX reagent (Invitrogen, Loughborough, UK) according to the manufacturer's protocol. Final siRNA treatment dosages were 2nM concentrated. All duplexes were purchased from Integrated DNA Technologies (Leuven, Belgium): anti-*HORAS5* (aka *Linc00161*) DsiRNA hs.Ri.LINC00161.13.2, anti-*BCL2A1* DsiRNAs hs.Ri.BCL2A1.13.1 and hs.Ri.BCL2A1.13.2 and non-targeting negative control (scramble) DS NC1. After 48 or 72 h post-transfection, treated cells were harvested for extracting total RNA and/or total protein.

### **Drug treatments**

5mg of cabazitaxel (Jevtana, Selleckchem, cat#S3022) was resuspended in DMSO in order to obtain a final stock solution of 5mM. 5mg of Enzalutamide (MDV3100, Selleckchem, cat#S1250) was resuspended in DMSO in order to obtain a final stock solution of 1mM. Both drugs were stored at -80°C. Carboplatin was resuspended in water to obtain a stock solution of 10mg/ml and stored at -20°C. All drugs were thawed at room temperature and diluted in cell culture media to treat the cells at different concentrations, according to the experiments:

- Cabazitaxel was used to treat LNCaP and DU145 cells for 24-48-72h at [5-50]nM in gene expression experiments, caspase assays, RNA sequencing and at [0.00005-0.0005-0.05-0.5-5-50-100]nM in the Trypan blue-based cell counting and IC<sub>50</sub> calculation experiments. 22rv1 were treated for 48-72h with 5-50 nM of cabazitaxel in gene expression experiments and Trypan blue-based cell counting.
- Enzalutamide was used to treat LNCaP [1-10]µM and 22rv1 [10-100]µM cells for 72h at in gene expression experiments.

- Carboplatin was used to treat DU145 cells for 72h at [1-10] $\mu$ M in gene expression experiments. All concentrations selected were clinically achievable.

All the drugs concentrations have been selected based on the IC<sub>50</sub> and concentrations used in the literature for CRPC cells, following a log<sub>10</sub> criteria, in order to select a wide range of concentrations for our analyses [28–31].

### **Trypan blue-based cell counting and IC<sub>50</sub> calculation**

Cell proliferation was assessed via Trypan blue-based cell counting; in this contest cell metabolic assays can give altered results due to taxane interference with mitochondria metabolism [32].

2 x 10<sup>5</sup> DU145-NC and -OE (and 22rv1-NC and -OE, suppl. fig. 4E) cells were seeded in a 6-well plate and treated with DMSO/cabazitaxel in the concentrations specified above (see drug treatments).

2.5 x 10<sup>5</sup> LNCaP cells and 5 x 10<sup>5</sup> DU145-OE cells were seeded in a 6-well plate and reverse transfected with 2nM of control siRNA and either anti-*HORAS5* siRNA or anti-*BCL2A1* siRNAs respectively. At day 2 post transfection, the cells were treated with DMSO/cabazitaxel in the concentrations specified above (see drug treatments).

For all the cells, at day 3 (LNCaP) and 2 (DU145-NC/-OE and 22rv1-NC/-OE) after the drug treatment trypan blue-based cell counting was performed and the in order to obtain the fraction of proliferating cells and calculate the IC<sub>50</sub> values by non-linear regression analysis (variable-slope inhibitor fitting), after normalization to untreated (DMSO) cells.

### **Caspase activity assay**

10<sup>4</sup> DU145-NC and -OE cells were seeded in a white, flat-bottom 96-well plate and treated with DMSO/5nM of cabazitaxel.

1.25 x 10<sup>4</sup> LNCaP cells and 2.5 x 10<sup>4</sup> DU145-OE cells were seeded in a white, flat-bottom 96-well plate and reverse transfected with 2nm of control siRNA and either anti-*HORAS5* siRNA or anti-*BCL2A1* siRNAs respectively. At day 2 post transfection the cells were treated with DMSO/5nM/50nM of cabazitaxel.

For all the cells, at day 3 (LNCaP) and 2 (DU145-NC and -OE) after the drug treatment Caspase-Glo reagent (Promega) was added to the cells and total luminescence was quantified following the manufacturer's protocol and normalized to time-match and treatment-match cell count.

### **RNA sequencing and differential expression analysis**

Total RNA samples were isolated from DU145-NC/OE cells untreated (DMSO) vs treated for 48h with 5nM of cabazitaxel. NGS based on the Ion Torrent Semiconductor technology (Thermo Fisher Scientific) and bioinformatics analysis were carried out by the Institute of Pathology of the University Hospital Basel, Switzerland. The resulting dataset was further analysed to determine the protein-coding

genes upregulated when *HORAS5* is overexpressed (DU145-OE) versus negative control (DU145-NC) upon cabazitaxel treatment (cabazitaxel-driven genes in fig.4A). The expression threshold was set as  $\log_2$  fold-change > 2 and p-value < 0.01 for the cells overexpressing *HORAS5*. The 87 genes were then filtered for DU145-NC p-value and sorted in descending order (top 25 genes in fig.4A). The final shortlist was obtained by ranking the top 3 genes based on literature evidence on cancer and taxane resistance.

### **Protein extraction and western blot analysis**

Cell lysates were obtained using 15-50-100  $\mu$ L of RIPA buffer (Tris pH 8.0 (Sigma Aldrich); NaCl (Sigma Aldrich); EDTA (Sigma Aldrich); Igepal (Sigma Aldrich); SDS (Sigma Aldrich), NaF (Sigma Aldrich); NaVO<sub>3</sub> (Sigma Aldrich)) according to the number of cells used. Proteins were quantified with the Peierce BCA assay (Thermo Fisher Scientific, Loughborough, UK) as per the manufacturer's protocol. 15  $\mu$ g of proteins were resolved via gel electrophoresis on reducing SDS-polyacrylamide gels (Tricine 10-20%, Thermo Fisher Scientific) run at 110V for 2 h. Protein transfer was performed using nitrocellulose membrane at 300mA for 2.5 h. The membranes were blocked in 8% skimmed milk dissolved in tris buffered saline (TBS; Sigma Aldrich) containing 0.1% tween-20 (TBS-T) at room temperature for 1h. After the 1h the blots were incubated overnight at 4°C with protein-specific primary antibodies dissolved in 5% BSA diluted in TBS-T for anti-BCL2A1 (Cell Signalling Technology, A1/Bfl-1 (D1A1C) Rabbit mAb, Cat# 14093) and 5% milk diluted in TBST for anti-GAPDH (Sigma Aldrich, cat# G9545). After the incubation blots were washed 3 times in TBS-T for 10 minutes each. Blots were then incubated with HRP-conjugated anti-rabbit secondary antibody (Fisher, cat#31460) dissolved in 8% milk diluted in TBS-T at room temperature for 1h. After the incubation, blots were washed 4 times in TBS-T for 10 min each.

After washing, ECL western blotting substrate kit was used (Millipore, Watford, UK) to visualise blot chemiluminescence, using Syngene Gbox with GeneTools software (Syngene, Bangalore, India).

### **CBioPortal analysis of clinical samples**

To assess the clinical relevance of *HORAS5* expression in PCa samples, CBioPortal (<http://www.cbioportal.org>) was queried using a publicly available Agilent microarray dataset [33]. This dataset consisted of a single study with 63 patients, of which 15 patients did not undergo chemotherapy treatment and 10 were treated with taxane only. We compared none versus taxane-only treatment.

### **Antisense oligonucleotides (ASOs)**

1.5 x 10<sup>5</sup> LNCaP and 1.5 x 10<sup>5</sup> DU145-NC cells were seeded in 6-well plates and after 24h the cells were transfected with 2nM of a negative control ASO (Eurofins genomics, ASO-NC: C\*C\*T \*T\*C\*C \*C\*T\*G \*A\*A\*G \*G\*T\*T \*C\*C\*T \*C\*C) and *HORAS5*-ASO3 (Eurofins Genomics, *HORAS5* V3\*:

G\*G\*C \*T\*G\*C \*T\*G\*C \*A\*T\*G \*T\*C\*T \*A\*C\*A \*G\*T) pre-selected as the most effective of 8 tested ASO sequences for *HORAS5* KD (fig.6A), using the RNAiMAX reagent (Invitrogen, Loughborough, UK), according to the manufacturer`s protocol. At day 2 post ASO treatment the cells were treated with DMSO/cabazitaxel at concentrations specified above (see drug treatments). At day 3 (LNCap) or day 2 (DU145-NC) post drug treatment the cells were counted using the tripan blue-based method.

### **Statistical Analysis**

All data were obtained from at least two or three independent experiments and analysed using GraphPad Prism 7 software. Values are presented as mean  $\pm$  standard deviation (SD). Significant differences between the groups were calculated using linear trend test, Student`s t-test, one-way ANOVA with Tukey`s multiple comparison post-test and two-way ANOVA with Sidak`s multiple comparison post-test and non-linear fit (log inhibitor vs. normalized response-Variable slope) IC<sub>50</sub> analysis. P value<0.05 was set as threshold for statistical significance. Outlier test was carried out to remove the extreme experimental replicate for the IC<sub>50</sub> calculation.



## Results

### ***HORAS5* overexpression and sub cellular localization**

Based on previously published data on *HORAS5* expression in a panel of PCa cells [22], we selected LNCaP (AR<sup>+</sup>) as cell line expressing this lncRNA and DU145 (AR<sup>-</sup>) as cell line with undetectable levels of *HORAS5* [22]. To investigate the effects of *HORAS5* in AR<sup>-</sup> PCa cells, *HORAS5* expression was artificially induced via DU145 cells' stable transduction with lentiviral particles containing *HORAS5* gene, expressed under the strong CMV promoter (fig.1A). This transduction induced elevated *HORAS5* expression, which was stable for at least 20 passages (fig.1B). We called these cells DU145-OE and the corresponding cells transfected with the empty vector were called DU145-NC. Additionally, we have confirmed *HORAS5* overexpression in AR<sup>+</sup> 22RV1 cells, which express undetectable endogenous levels of *HORAS5* (supplementary figure 4A). Our previous studies showed that *HORAS5* is located in the cytoplasm of LNCaP cells [22]. Our results in DU15-OE cells indicate that the artificial expression of this lncRNA preserved its cytoplasmic location (fig.1C). Our analyses in 22rv1-OE also confirmed *HORAS5* cytoplasmic location (suppl.fig.4B). Additionally, we observed no morphological changes induced by *HORAS5* overexpression in DU145-OE vs DU145-NC and DU145-WT (fig.1D) and *HORAS5* overexpression did not influence cell proliferation in untreated cells (fig.1E).

### ***HORAS5* expression is induced by cabazitaxel in a concentration- and time-dependent manner**

Since our previous studies have shown *HORAS5* upregulation in CRPC vs. hormone sensitive PDXs [22] and other studies suggested that *HORAS5* modulates drug response [13,21], we sought to investigate whether exposure to clinically employed drugs could affect the expression of *HORAS5*. To this aim, we selected three drugs, which are representative of the most commonly used treatments in CRPC patients: the AR inhibitor enzalutamide, which is used in AR<sup>+</sup> CRPC [5,34,35]; the microtubule inhibitor cabazitaxel, which is active against both AR<sup>+</sup> and AR<sup>-</sup> CRPCs [36,37]; the platinum agent carboplatin, which displayed some activity in AR<sup>-</sup> CRPCs [38,39] (tab.1). In line with clinical indications, enzalutamide was used in LNCaP and 22rv1-OE cells, carboplatin in DU145-OE cells only and cabazitaxel in all the cell lines with doses ranging around the IC<sub>50</sub> and concentrations found in the literature for CRPC cells, on a log<sub>10</sub> basis [28–31]. Based on our criteria ( $p < 0.05$  and  $R^2 > 0.5$ ) Enzalutamide did not determine a significant change in *HORAS5* expression in LNCaP ( $p = 0.2451$ ,  $R^2 = 0.06073$ ) (fig.2A) and 22rv1-OE cells ( $p = 0.0029$ ,  $R^2 = 0.3195$ ) (suppl.fig.4C) at the clinically achievable concentrations used [40]. Similarly, no effect was observed for carboplatin ( $p = 0.0061$ ,  $R^2 = 0.1657$ ) (fig.2B) [41,42]. Cabazitaxel induced a concentration-dependent increase of *HORAS5* expression in LNCaP ( $p < 0.0001$ ,  $R^2 = 0.6513$ ) (fig.2C), DU145-OE ( $p < 0.0001$ ,  $R^2 = 0.7563$ ) (fig.2D) and 22rv1-OE cells ( $p < 0.0001$ ,  $R^2 = 0.7185$ ) (suppl.fig.4D). All the concentrations of cabazitaxel used in these experiments are clinically achievable [43]. Overall, just cabazitaxel treatment determined a linear concentration-dependent increase in the expression of *HORAS5* ( $R^2 > 0.5$  linear trend test). A time-

course experiment revealed that cabazitaxel-induced *HORAS5* upregulation is time-dependent: we did not observe any significant transcript upregulation up to 24h after treatment. However, *HORAS5* was significantly upregulated in DU145 (48h, 72h) and in LNCaP (72h) cells (fig.2E, F). For this reason, we chose 72h for LNCaP and 48h for DU145-OE as time points for further experiments.

### ***HORAS5* modulation affects the proliferation and survival of prostate cancer cells exposed to cabazitaxel**

So far, we have shown that cabazitaxel induces a dose- and time-dependent increase in *HORAS5* expression in both AR<sup>+</sup> and AR<sup>-</sup> CRPC cells. We therefore sought to investigate the functional significance of *HORAS5* in CRPC cells exposed to cabazitaxel. We optimized the silencing procedure and obtained a KD of 77%, at day 5 after transfection (suppl.fig.1A). This time-point results from 2 days of silencing + 3 additional days of cabazitaxel treatment. We then hypothesized that *HORAS5* silencing and overexpression can affect CRPC cell proliferation. We analysed the effect of *HORAS5* modulation on cabazitaxel anticancer activity. Our data showed that cabazitaxel induced a dose-dependent growth inhibition (fig.3A,B). This inhibition decreased in DU145-OE compared to DU145-NC (fig.3A) with a significant increase of cabazitaxel IC<sub>50</sub> of 9.8 times (from 3.11 ± 1.48nM to 30.55±3.9 nM, suppl.fig.1B) in the cells that overexpress *HORAS5* (p-value=0.0114) (fig.3C). Vice versa, cabazitaxel-dependent growth inhibition increased in LNCaP cells upon *HORAS5* KD (fig.3B). Our calculation showed that *HORAS5* silencing caused dramatic decrease of cabazitaxel IC<sub>50</sub> in this cell line (from 20.80±0.74 nM to 2.59±0.77 nM, p-value=0.0033) (fig.3D, suppl.fig.1B). These results demonstrate that *HORAS5* promotes the survival of both AR<sup>+</sup> and AR<sup>-</sup> CRPC cells exposed to cabazitaxel. In order to investigate the role of the apoptotic pathway in this phenomenon, we measured caspase 3/7 activity in LNCaP and DU145 cells exposed to cabazitaxel. Our data showed that *HORAS5* overexpression significantly reduced caspase 3/7 activation in response to cabazitaxel exposure (fig.3E). In keeping with this result, *HORAS5* KD increased caspase 3/7 activation in LNCaP cells exposed to cabazitaxel (fig.3F). Overall, these findings indicated that *HORAS5* promoted cabazitaxel resistance in both AR<sup>+</sup> and AR<sup>-</sup> PCa cells via increase of cell proliferation and inhibition of caspase-mediated apoptosis.

### ***BCL2A1* expression is induced by cabazitaxel and increased with *HORAS5* expression**

To evaluate the transcriptomic profile of CRPC cells exposed to cabazitaxel and the effects of *HORAS5* modulation, we performed an NGS transcriptome analysis (suppl.fig.2A-E) using the following samples: DU145-NC, untreated; DU145-NC, exposed to cabazitaxel; DU145-OE, untreated; DU145-OE, exposed to cabazitaxel. Based on this analysis 87 genes were significantly up-regulated (Fold Change (FC) ≥2, p value<0.01) in DU145-OE treated with cabazitaxel vs untreated cells (fig.4A). Notably, these genes were not significantly upregulated in DU145-NC exposed to cabazitaxel (fig.4A). We then ranked these 87 genes according to the DU145-NC p-value and shortlisted the top 25 (fig.4A,

suppl.tab.1). Three of these 25 genes (*SOX9*, *CCL20*, *BCL2A1*) have been previously implicated in cancer and drug resistance [44–48] (fig.4A). Hence, we sought to validate our transcriptome results by measuring the expression of *SOX9*, *CCL20* and *BCL2A1* via RT-qPCR. No significant differences in *SOX9* expression were found (fig.4B). *CCL20* and *BCL2A1* were both significantly upregulated in the *HORAS5* expressing cells vs negative control upon cabazitaxel exposure. This differential expression pattern was particularly significant for *BCL2A1* (fig.4C, D), which is also a well-described anti-apoptotic gene [47,49,50]. For this reason, we decided to investigate the role of *BCL2A1* in *HORAS5*-dependent cabazitaxel resistance. First, we confirmed that *BCL2A1* protein expression was induced by cabazitaxel treatment (fig.4E). According to our results *BCL2A1* seemed to be the most consistently up-regulated gene in cabazitaxel-treated cells that overexpress *HORAS5*. Therefore, we investigated whether *BCL2A1* KD could rescue the drug-resistant phenotype induced by *HORAS5* overexpression.

### **Knockdown of *BCL2A1* decreases cell proliferation and increases apoptosis in CRPC cells exposed to cabazitaxel treatment**

Based on our transcriptomic analysis, we hypothesized that *BCL2A1* mediates the drug-resistance phenotype induced by *HORAS5*. To test this hypothesis, we optimized the KD procedure using 2 different siRNAs directed against both variants of *BCL2A1* mRNA. Our results show that siRNA1 and siRNA2 determined a reduction in *BCL2A1* mRNA of 84% and 95% respectively (fig.5A). Our results also showed that both siRNAs reduced the expression of *BCL2A1* protein (fig.5B). These two siRNAs were used to transfect DU145-OE cells in order to investigate whether *BCL2A1* KD could revert the cabazitaxel resistance phenotype induced by *HORAS5* overexpression. Our data showed that *BCL2A1* KD significantly reduced DU145-OE resistance to cabazitaxel (fig.5C). We also tested whether *BCL2A1* effect on cabazitaxel response was a consequence of its anti-apoptotic activity. As we showed in figure 5D *BCL2A1* KD determined a small increase in apoptosis in untreated cells (fig.5D). However, *BCL2A1* KD caused a highly significant increase in apoptosis when the cells are exposed to both 5 nM ( $1.98 \leq FC \leq 2.21$ ,  $p < 0.0001$ ) and 50nM ( $3.06 \leq FC \leq 4.36$ ,  $p < 0.0001$ ) cabazitaxel. These findings show that *BCL2A1*, which is upregulated upon *HORAS5* expression, enhances cabazitaxel resistance by inhibiting the apoptosis response.

### **Translational research: ASO directed against *HORAS5* can decrease cabazitaxel IC<sub>50</sub> and implications of *HORAS5* expression for the clinics**

Since *HORAS5* modulation via lentiviral-driven overexpression and siRNA-mediated KD affected cabazitaxel resistance, we investigated *HORAS5* expression in clinical PCa samples from a published study [33], accessed via cBioPortal. *HORAS5* expression was significantly higher ( $p$  value= 0.0086) in metastatic samples from patients treated with taxanes than in untreated patients (fig.6A). Given this evidence, we analysed if *HORAS5* could effectively be silenced using antisense oligonucleotides (ASOs). Since ASOs are currently used in clinical trials [51–53], we thought that this set of experiments

could highlight the therapeutic potential of targeting lncRNAs like *HORAS5* in the clinical setting. For this set of experiments, we used LNCaP cells, which express endogenous detectable levels of *HORAS5*. We tested 8 different ASOs and found that ASO3 was the most effective inhibitor of *HORAS5* expression (78.2%) (fig.6B, suppl. fig.3). Hence, we tested ASO3 in combination with cabazitaxel to analyse if this *HORAS5*-targeting ASO influenced cabazitaxel IC<sub>50</sub>. Our results showed that the *HORAS5*-targeting ASO determined a decrease in the cell count upon cabazitaxel treatment and therefore a significant decrease in the IC<sub>50</sub> (FC=6.55, p=0.0034) (fig.6C-D). To rule out off-target effects, we have tested ASO3 in DU145-NC cells, which express undetectable levels of *HORAS5*. ASO3 does not affect *HORAS5* expression (suppl.fig.5A) neither cabazitaxel effect on cell count of DU145-NC (suppl.fig.5B). This evidence showed that ASO-directed *HORAS5* KD decreased cabazitaxel resistance in LNCaP cells and that its role *in vivo* should be further evaluated. Overall, these findings suggested that *HORAS5* could have a clinical relevance and paved the way to *HORAS5* targeting in combination with taxanes to increase drug response in CRPC patients.

## Discussion

CRPC is an incurable malignancy [4], therefore there is an urgent need to find novel diagnostic and prognostic biomarkers and effective therapeutic targets. Recent findings showed that lncRNAs can have a determinant role in drug response pathways in some cancers [13,17–21]. Therefore, we hypothesized that lncRNAs may act as promoters of CRPC aggressive phenotypes.

Our previous work showed that the lncRNA *HORAS5* (i.e. linc00161) was upregulated in CRPC PDXs and increased the survival of AR<sup>+</sup> CRPC cells [22] while a previous study showed that *HORAS5* decreased the survival of cisplatin-treated osteosarcoma cells [13]. Based on other studies showing the multifaceted roles of lncRNAs in different cancers [13,21,54–56] we investigated if this particular lncRNA was involved in drug response in CRPC, using a panel of clinically used drugs at achievable concentrations [40–43] (see drug treatments section in Materials & Methods). In this study we have shown for the first time a specific cabazitaxel-driven induction of *HORAS5* expression, using our new model of CRPC cells with lentiviral-induced *HORAS5* overexpression (fig.7). Cabazitaxel is clinically approved for the treatment of advanced CRPCs that acquired resistance to docetaxel [8,36,37,57]. So far, there is no evidence implicating lncRNAs in cabazitaxel response.

Since we had already characterized *HORAS5* in untreated AR<sup>+</sup> cells and targeted it with siRNAs [22], we wanted to investigate if *HORAS5* overexpression changed or maintained the endogenous subcellular localization. While cytoplasmic molecules are easier to target, nuclear membrane-crossing carriers are needed for nuclear targets. lncRNA subcellular localization can also be predictive of its putative mechanism of action. Indeed, lncRNAs are often found to interact with miRNAs as ceRNAs when they act in the cytoplasm. Other studies have shown that lncRNAs can act also in the nucleus via interaction with protein complexes such as epigenetic and splicing factors [58–60]. Since our data indicated that *HORAS5* overexpression promoted a mainly cytoplasmic localization pattern, we hypothesized that it could be effectively targeted and that it could interact with cytoplasmic molecules and complexes [61,62].

Our data show that *HORAS5* overexpression increases cabazitaxel resistance via regulation of apoptotic signals. This is consistent with previous studies implicating lncRNAs as regulators of cell apoptosis [63,64] and as mediators of drug resistance [65,66]. In AR<sup>+</sup> PCa cell, *HORAS5* acts mainly by stabilising the *AR* mRNA, thereby activating AR-target genes, such as the oncogenic *KIAA0101* [22]. Since the AR pathway is a main mediator of taxane resistance [67–69], this mechanism of action explains the increased cabazitaxel sensitivity of LNCaP cells upon *HORAS5* KD. However, our data on DU145 cells indicate that *HORAS5* could mediate taxane-resistance via AR-independent mechanisms. Hence, we decided to investigate additional *HORAS5* mechanisms of action in AR<sup>-</sup> cells. From NGS transcriptome analysis, *BCL2A1* resulted as the most differentially *HORAS5*-upregulated gene upon cabazitaxel treatment. *BCL2A1* encodes for an anti-apoptotic factor [47,49,50] already described to

participate in drug resistance phenotypes [47,48,70]. Currently there are no studies which implicate BCL2A1 in cabazitaxel response. Hence, we evaluated the effect of *BCL2A1* KD on the drug-resistant phenotype induced by *HORAS5* overexpression. Our system efficiently silenced *BCL2A1* in untreated PCa cells (KD efficiency 90%). However, in these conditions we did not observe a striking cell count reduction. This could be attributed to the fact that BCL2A1 levels are relatively low in untreated PCa cells. However, in the presence of cabazitaxel, BCL2A1 levels are highly increased. In these conditions, we observed an additive effect between BCL2A1 KD and cabazitaxel treatment. Taken together, our data indicate that BCL2A1 facilitates the drug-resistance phenotype induced by *HORAS5* by promoting AR<sup>-</sup> CRPC cell survival (fig.7). Although the specific mechanism by which *HORAS5* and *BCL2A1* interact needs to be clarified by further studies, we suggest that *HORAS5* could sequester one or more miRNAs which inhibit *BCL2A1* translation. For example, mir-128 has been shown to bind *HORAS5* in ovarian cancer cells [21]. Interestingly, *BCL2A1* is one of the predicted targets of this miRNA. Moreover, in line with our previous findings on *HORAS5* mechanism of action in AR<sup>+</sup> LNCaP cells [22], we also suggest that *HORAS5* could directly interact with *BCL2A1*, thereby stabilizing and protecting its mRNA. In keeping with this hypothesis, our *in-silico* predictions suggested that *HORAS5* and *BCL2A1* have common miRNAs binding sites. Finally, we would like to point out that the BCL2A1-dependent mechanism of action characterised in this study is likely one of several ways by which *HORAS5* mediates taxane resistance in AR<sup>-</sup> cells. Our transcriptomic data identified also other downstream effectors of this lncRNA such as the top 25 genes reported in supplementary table1. This is in line with the pleiotropic mechanism of action displayed by other lncRNAs [71].

We have also shown that *HORAS5* overexpression in untreated AR<sup>-</sup> PCa cells does not affect cellular features such as cell shape and proliferation. This observation seems to be in contrast with our previous study, which showed that *HORAS5* KD decreases AR<sup>+</sup> PCa growth and survival[22]. This discrepancy could be explained by the different gene modulating approaches employed (transient silencing vs stable over-expression) and by the fact that *HORAS5* seems to act via different mechanisms in AR<sup>+</sup> and AR<sup>-</sup> PCa cells: activation of the AR-pathway in the former, up-regulation of BCL2A1 and other anti-apoptotic genes in the latter (particularly in response to pro-apoptotic stimuli).

## Conclusion

Our findings highlight the potential of *HORAS5* in translational studies. The clinical relevance of *HORAS5* was assessed by our analyses on database's available data [33]. Indeed, we have shown that *HORAS5* is significantly up-regulated in PCa metastatic samples from patients treated with taxanes compared to taxane-untreated patients. Moreover, the possibility to detect *HORAS5* in biological fluids (i.e. urine and blood) could pave the way for the use of this lncRNA as non-invasive biomarker for treatment response as well as novel therapeutic target for CRPC. In this context we designed a specific antisense molecule (ASO3) capable of effectively inhibiting *HORAS5* expression *in vitro*, thereby reducing cabazitaxel resistance in CRPC cells (fig.7). We would like to point out that our silencing

experiments reduced the chance of off-target effects in many ways: both IDT siRNAs and ASOs were designed to uniquely match *HORAS5* sequence; we used appropriate negative controls at each step; we used two different silencing methods, obtaining very similar results. Hence, we are confident that the phenotypic effects observed in this study are uniquely attributable to the silencing of *HORAS5*.

Since ASOs have been successfully employed in clinical trials [51–53], the use of *HORAS5* ASOs in combination with cabazitaxel could increase CRPC patients` drug sensitivity and their survival. Therefore, our findings could bring novel insights in the fields of personalized medicine and innovative diagnostic strategies.

## Future perspective

*HORAS5* is a lncRNA upregulated in different cancers, including CRPC. It has been recently shown that *HORAS5* promotes drug resistance in ovarian cancer. Our work revealed the role of *HORAS5* in CRPC drug resistance and identified a mechanism of action by which *HORAS5* inhibits cabazitaxel-induced apoptosis. In light of this evidence, we proposed a novel approach (ASO-mediated gene silencing) to inhibit this oncogenic lncRNA. This approach could be used *in vivo* in future studies and in clinical trials. In the next steps of this work, we plan to test *HORAS5*-targeting ASOs using *in vivo* cancer models. We also plan to further investigate *HORAS5* expression in clinical samples, especially in biological fluids in order to clarify *HORAS5* potential as a non-invasive biomarker for cancer diagnosis and treatment response monitoring. With this future perspective, we are planning to collect urine and plasma samples from PCa patients, before and after treatment with cabazitaxel and to treat CRPC animal models with cabazitaxel and *HORAS5*-ASO combination treatments. Moreover, further mechanistic studies on *HORAS5* action in this context will give more insights on the interaction of *HORAS5* with BCL2A1 and other molecules, paving the way for the discovery of novel molecular pathways and additional targets to reduce cabazitaxel resistance and increase patient survival.

## Summary points

- Since *HORAS5* was upregulated in CRPC PDXs according to our previous publication, we evaluated if *HORAS5* was involved in treatment resistance.
- We showed that *HORAS5* expression was highly increased upon cabazitaxel treatment in both AR<sup>+</sup> and AR<sup>-</sup> CRPC cells.
- *HORAS5* KD and overexpression affected cabazitaxel response, suggesting that *HORAS5* promoted resistance to this drug by increasing cells proliferation and inhibiting caspase-mediated apoptosis.
- We found that *HORAS5* upregulated the anti-apoptotic factor BCL2A1.
- BCL2A1 KD reverted cabazitaxel resistance phenotype promoted by *HORAS5* overexpression in AR<sup>-</sup> CRPC cells. This finding confirmed that *HORAS5* promoted cabazitaxel resistance by upregulating BCL2A1, thereby inhibiting drug-induced apoptosis.
- *HORAS5* was found upregulated in taxane treated clinical samples; this finding emphasizes the translational potential of inhibiting *HORAS5*.
- Due to these findings, *HORAS5* expression was successfully inhibited in CRPC cells, using ASOs that can be used in future clinical studies. One of our *HORAS5* targeting ASOs decreased cabazitaxel IC<sub>50</sub> showing reduction of *HORAS5*-induced drug resistance.



## Figure legends

**Figure 1. *HORAS5* overexpression maintains its cytoplasmic location and does not affect cell proliferation and morphology.** **A.** Schematic representation of the vector LPP-GS266B-Lv105-050 used to induce the expression of *HORAS5* in the transduced cells (DU145). The plasmid contains the LTR packaging elements the CMV strong promoter, the pUC Ori bacteria-start replication site and the antibiotic resistance cassettes to select the cells transduced and containing *HORAS5*. **B.** qPCR expression of *HORAS5* (aka *linc00161*) in AR<sup>+</sup> PCa cells with endogenous expression of the lncRNA (LNCaP) and AR<sup>-</sup> PCa cells with lentivector-induced expression (DU145-OE). **C.** qPCR expression of *HORAS5* in the nuclear and cytoplasmic subcellular fractions of DU145-OE cells. *GAPDH* and *MALAT1* are used as controls for cytoplasmic and nuclear fractions, respectively. *HPRT1* was used as housekeeping gene for data normalization in all the qPCR experiments. **D, E.** Pictures of DU145-WT, DU145-NC and DU145-OE cells` morphology (D) and MTS proliferation curves of DU145-OE vs DU145-WT (E). The size bars in figure D represent 100µm. Results expressed as means ± S.D. from two independent replicates. Two-way ANOVA with Sidak`s post-test was performed for statistical comparison in E.

**Figure 2. Effect of commonly used drugs in the clinics on *HORAS5* expression and selection of cabazitaxel.** **A-D.** qPCR expression of *HORAS5* and reported *cMAX* and experimental concentrations upon treatment with enzalutamide (LNCaP, A.), carboplatin (DU145-OE, B.) and cabazitaxel (LNCaP, C.; DU145-OE, D.) drugs on LNCaP AR<sup>+</sup> and DU145 AR<sup>-</sup> PCa cell lines for 72h. Results expressed as means ± S.D. from two independent replicates. One-way ANOVA with Tukey`s post-test was performed for statistical comparison \*\*P=0.0061, \*\*\*\*P<0.0001. **E,F.** Expression of *HORAS5* at different concentrations and different time-points of cabazitaxel treatment in LNCaP (E.) and DU145-OE (F.). Results expressed as means ± S.D. from two independent replicates. Two-way ANOVA with Sidak`s post-test was performed for statistical comparison \*\*\*\*P<0.0001.

**Figure 3. *HORAS5* silencing and overexpression affect PCa cells proliferation and survival under cabazitaxel exposure.** **A-D.** DU145 (A.) and LNCaP (B.) cell count upon 48h (DU145) and 72h (LNCaP) of cabazitaxel treatment, with *HORAS5* overexpression and silencing respectively, compared to the respective negative controls, and resulting IC<sub>50</sub>s (C., DU145; D., LNCaP).; cell count is expressed as nonlinear fit curves of the cell number in percentage normalized to the untreated (DMSO) control. Two-way ANOVA with Sidak`s post-test was performed for statistical comparison \*P= 0.0230, \*\*\*P< 0.0005, \*\*\*\*P<0.0001 and nonlinear fit was used to calculate the IC<sub>50</sub>s. Student t-test was used in C. and D. **E, F.** Caspase 3/7 activity normalized to relative cells number 48h after cabazitaxel treatment (DU145) and 48h post-transfection of *HORAS5*-siRNA + 72h after cabazitaxel treatment (LNCaP). One-way ANOVA with Tukey`s post-test was used in E. and F. for statistical comparison \*\*\*\*P<0.0001. Results expressed as means ± S.D. from three independent replicates.

**Figure 4. *BCL2A1* is the most consistently upregulated gene in PCa cells with *HORAS5* overexpression and is induced by cabazitaxel.** **A.** Flow chart showing the method used to shortlist cabazitaxel-driven genes in PCa cells that overexpress *HORAS5* (DU145-OE vs DU145-NC) from RNA sequencing. **B-D.** qPCR validation of the 3 shortlisted genes: SOX9, CCL20 and BCL2A1. **E.** BCL2A1 expression is significantly increased at the protein level upon cabazitaxel treatment in the cells that overexpress *HORAS5* (DU145-OE). Results expressed as means  $\pm$  S.D. from four independent experiments in B-D. One-way ANOVA with Tukey's post-test was used in for statistical comparison \*P=0.049, \*\*P<0.002, \*\*\*\*P<0.0001.

**Figure 5. *BCL2A1* silencing decreases cell proliferation and increases apoptosis in CRPC cells exposed to cabazitaxel.** **A, B.** *BCL2A1* expression is significantly reduced at the mRNA (A) and protein (B) level upon knock-down (GAPDH was used as Western blot loading control). **C.** Cell count upon cabazitaxel treatment, with *BCL2A1 KD* in cells that overexpress *HORAS5* (DU145-OE); cell count is expressed as percentage normalized to the untreated (DMSO) control. **D.** Caspase 3/7 activity normalized to relative cell number in DU145-OE cells upon 48h BCL2A1 KD + 48h of cabazitaxel treatment. Results expressed as means  $\pm$  S.D. from three independent replicates. One-way ANOVA with Tukey's post-test was used in for statistical comparison \*P<0.05, \*\*P<0.01, \*\*\*P<0.001, \*\*\*\*P<0.0001. Western blots are visualised using Syngene Genesys software.

**Figure 6. Clinical relevance of *HORAS5*: ASO-mediated inhibition to decrease cabazitaxel resistance and expression in clinical samples.** **A.** *HORAS5* expression from patients' metastatic samples treated with taxanes-only compared to untreated. **B.** *HORAS5* expression was significantly reduced upon treatment with our specifically designed ASO (ASO3) (A). **C, D.** *HORAS5* KD mediated by ASO3 (48h) induced a decrease in the cell count upon cabazitaxel treatment (72h) (C) and a reduction in the IC<sub>50</sub> (D). Cell count is expressed as nonlinear fit curves of the cell number in percentage, normalized to the untreated (DMSO) control. Results expressed as means  $\pm$  S.D. from three independent replicates. Two-way ANOVA with Sidak's post-test was performed for statistical comparison \*\*P=0.0056. Student t-test was used for statistical comparison in A and D \*\*P=0.0081 and P=0.0034.

**Figure 7: Diagram summarising our findings.** CRPC cells treated with cabazitaxel show up-regulation of *HORAS5* that could happen via *HORAS5* gene transcriptional activation or degradation inhibition. *HORAS5* up-regulation increases BCL2A1 expression and this decreases apoptosis and increases cell proliferation. In response to cabazitaxel treatment this pathway enhances drug resistance. When *HORAS5* is inhibited via a specifically designed ASO, *HORAS5* levels highly decrease causing a decrease in cabazitaxel resistance.

## References

Papers of special note are highlighted as \* - of interest and \*\* - of particular interest

1. Chandrasekar T, Yang J, Gao A, Evans CP. Mechanisms of resistance in castration-resistant prostate cancer (CRPC). *Transl. Androl. Urol.* 4(3), 365–80 (2015).
2. Gao L, Schwartzman J, Gibbs A, *et al.* Androgen Receptor Promotes Ligand-Independent Prostate Cancer Progression through c-Myc Upregulation. *PLoS One.* 8(5), 1–10 (2013).
3. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. *Oncogene.* 32(49), 5501–5511 (2013).
4. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. *Int. J. Clin. Pract.* 65(11), 1180–92 (2011).
5. Beer TM, Armstrong AJ, Rathkopf DE, *et al.* Enzalutamide in metastatic prostate cancer patients before chemotherapy. *N. Engl. J. Med.* 371(5), 424–433 (2014).
6. Ryan CJ, Smith MR, De Bono JS, *et al.* Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy. *N. Engl. J. Med.* 368(2), 138–148 (2013).
7. Petrylak DP, Tangen CM, Hussain MHA, *et al.* Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer. *N. Engl. J. Med.* 351(15), 1513–1520 (2004).
8. De Bono JS, Oudard S, Ozguroglu M, *et al.* Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. *Lancet.* 376(9747), 1147–1154 (2010).
9. Iyer MK, Niknafs YS, Malik R, *et al.* The Landscape of Long Noncoding RNAs in the Human Transcriptome. *Nat. Genet.* 47(3), 199–208 (2015).
10. Zampetaki A, Albrecht A, Steinhofel K. Long non-coding RNA structure and function: Is there a link? *Front. Physiol.* 9(AUG), 1–8 (2018).
11. Cao T, Jiang Y, Wang Z, *et al.* H19 lncRNA identified as a master regulator of genes that drive uterine leiomyomas. *Oncogene.* 38(7), 5356–5366 (2019).
12. Shan Y, Ma J, Pan Y, Hu J, Liu B, Jia L. LncRNA SNHG7 sponges MIR-216b to promote proliferation and liver metastasis of colorectal cancer through upregulating GALNT1. *Cell Death Dis.* 9(7) (2018).
13. Wang Y, Zhang L, Zheng X, *et al.* Long non-coding RNA LINC00161 sensitises osteosarcoma cells to cisplatin-induced apoptosis by regulating the miR-645-IFIT2 axis.

*Cancer Lett.* 382(2), 137–146 (2016).

\*\* The first published study on *HORAS5* and showed *HORAS5* increase upon drug treatment. Additionally, *HORAS5* was shown to increase apoptosis in response to cisplatin treatment in OS cells.

14. Chalei V, Sansom SN, Kong L, *et al.* The long non-coding RNA Dali is an epigenetic regulator of neural differentiation. *Elife.* 3, 1–24 (2014).
15. Zhai W, Zhu R, Ma J, *et al.* A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma. *Mol. Cancer.* 18(1), 1–15 (2019).
16. Malek R, Gajula R, Williams R, *et al.* TWIST1-WDR5-Hottip Regulates Hoxa9 Chromatin to Facilitate Prostate Cancer Metastasis. *Cancer Res.* 77(12), 3181–3193 (2017).
17. Li P, Zhang X, Wang H, *et al.* MALAT1 Is Associated with Poor Response to Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients and Promotes Chemoresistance through EZH2. *Mol. Cancer Ther.* 16(4), 739–751 (2017).
18. Tan DSW, Chong FT, Leong HS, *et al.* Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma. *Nat. Med.* 23(10), 1167–1175 (2017).
19. Pucci P, Rescigno P, Sumanasuriya S, de Bono J, Crea F. Hypoxia and Noncoding RNAs in Taxane Resistance. *Trends Pharmacol. Sci.* 39(8), 695–709 (2018).
20. Huang K-C, Rao PH, Lau CC, *et al.* Relationship of XIST expression and responses of ovarian cancer to chemotherapy. *Mol. Cancer Ther.* 1(10), 769–76 (2002).
21. Xu M, Zhou K, Wu Y, Wang L, Lu S. Linc00161 regulated the drug resistance of ovarian cancer by sponging microRNA-128 and modulating MAPK1. *Mol. Carcinog.* 58(4), 577–587 (2019).

\*\* The most recent publication on *HORAS5* and showed that this lncRNA acted as oncogene in ovarian cancer, promoting drug resistance as ceRNA of miR-128.

22. Parolia A, Venalainen E, Xue H, *et al.* The long noncoding RNA *HORAS5* mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. *Mol. Oncol.* 13(5), 1121–1136 (2019).

\*\* Characterized *HORAS5* in PCa for the first time and showed high levels of this lncRNA in CRPC PDXs and cells. This study also showed that *HORAS5* increased cells growth and inhibited apoptosis via regulation of the AR signalling in AR<sup>+</sup> CRPC cells.

23. Xu L-C, Chen Q-N, Liu X-Q, *et al.* Up-regulation of LINC00161 correlates with tumor migration and invasion and poor prognosis of patients with hepatocellular carcinoma.

*Oncotarget*. 8(34), 56168–56173 (2017).

\*\* Showed that *HORAS5* correlated with aggressive phenotypes in HCC, confirming *HORAS5*'s role as oncogene in different cancers.

24. Sedelaar JPM, Isaacs JT. Tissue culture media supplemented with 10% fetal calf serum contains a castrate level of testosterone. *Prostate*. 69(16), 1724–1729 (2009).
25. Tsauro I, Heidegger I, Kretschmer A, *et al.* Aggressive variants of prostate cancer – Are we ready to apply specific treatment right now? *Cancer Treat. Rev.* 75(December 2018), 20–26 (2019).
26. Beltran H, Tomlins S, Aparicio A, *et al.* Aggressive Variants of Castration Resistant Prostate Cancer. *Clin Cancer Res.* 20(11), 2846–2850 (2014).
27. Denning W, Das S, Guo S, Xu J, Kappes J, Hel Z. Optimization of the transductional efficiency of lentiviral vectors: effect of sera and polycations. *Mol Biotechnol.* 53(3), 308–314 (2013).
28. Mukhtar E, Adhami VM, Siddiqui IA, Verma AK, Mukhtar H. Fisetin enhances chemotherapeutic effect of cabazitaxel against human prostate cancer cells. *Mol Cancer Ther.* 15(12), 2863–2874 (2016).
29. Ríos-Colón L, Cajigas-Du Ross CK, Basu A, *et al.* Targeting the stress oncoprotein LEDGF/p75 to sensitize chemoresistant prostate cancer cells to taxanes. *Oncotarget*. 8(15), 24915–24931 (2017).
30. Yadav SS, Li J, Stockert JA, *et al.* Combination effect of therapies targeting the PI3K- and ARsignaling pathways in prostate cancer. *Oncotarget*. 7(46), 76181–76196 (2016).
31. McPherson RAC, Galettis PT, de Souza PL. Enhancement of the activity of phenoxodiol by cisplatin in prostate cancer cells. *Br. J. Cancer*. 100(4), 649–55 (2009).
32. Varbiro G, Veres B, Gallyas FJ, Sumegi B. Direct effect of Taxol on free radical formation and mitochondrial permeability transition. *Free Radic Biol Med.* 31(4), 548–58 (2001).
33. Kumar A, Coleman I, Morrissey C, *et al.* Substantial inter-individual and limited intra-individual genomic diversity among tumors from men with metastatic prostate cancer. *Nat. Med.* 22(4), 369–378 (2016).
34. Scher H, Fizazi K, Saad F, *et al.* Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. *N. Engl. J. Med.* 367(13), 1187–1197 (2012).
35. Hussain M, Fizazi K, Saad F, *et al.* Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. *N. Engl. J. Med.* 378(26), 2465–2474 (2018).

36. Smiyun G, Azarenko O, Miller H, *et al.*  $\beta$ III-tubulin enhances efficacy of cabazitaxel as compared with docetaxel. *Cancer Chemother. Pharmacol.* 80(1), 151–164 (2017).
  37. Sissung TM, Price DK, Del Re M, *et al.* Genetic variation : effect on prostate cancer. *Biochim Biophys Acta.* 1846, 446–456 (2014).
  38. Aparicio AM, Harzstark AL, Corn PG, *et al.* Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer. *Clin Cancer Res.* 19(13), 3621–3630 (2013).
  39. Fléchon A, Pouessel D, Ferlay C, *et al.* Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: Results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. *Ann. Oncol.* 22, 2476–2481 (2011).
  40. Gibbons JA, Ouatas T, Krauwinkel W, *et al.* Clinical Pharmacokinetic Studies of Enzalutamide. *Clin. Pharmacokinet.* 54, 1043–1055 (2015).
  41. Kern W, Braess J, Friedrichsen S, Kaufmann CC, Schleyer E, Hiddemann W. Carboplatin pharmacokinetics in patients receiving carboplatin and paclitaxel/docetaxel for advanced lung cancers: Impact of age and renal function on area under the curve. *J. Cancer Res. Clin. Oncol.* 127, 64–68 (2001).
  42. Fukuda M, Oka M, Soda H, *et al.* Phase I study of Irinotecan combined with carboplatin in previously untreated solid cancers. *Clin Cancer Res.* 5(12), 3963–3969 (1999).
  43. Diéras V, Lortholary A, Laurence V, *et al.* Cabazitaxel in patients with advanced solid tumours: Results of a Phase i and pharmacokinetic study. *Eur. J. Cancer.* 49(1), 25–34 (2013).
  44. Song W, Kwon GY, Kim JH, *et al.* Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer. *Oncotarget.* 7(50), 83735–83743 (2016).
  45. Zhang C yang, Qi Y, Li X nan, *et al.* The role of CCL20/CCR6 axis in recruiting Treg cells to tumor sites of NSCLC patients. *Biomed. Pharmacother.* 69, 242–248 (2015).
  46. Chen W, Qin Y, Wang D, *et al.* CCL20 triggered by chemotherapy hinders the therapeutic efficacy of breast cancer. *PLoS Biol.* 16(7), 1–27 (2018).
  47. Haq R, Yokoyama S, Hawryluk EB, *et al.* BCL2A1 is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibition . *Proc. Natl. Acad. Sci.* 110(11), 4321–4326 (2013).
- \* Characterized *BCL2A1* as an oncogene with antiapoptotic roles in cancers and showed that it conferred drug resistance to melanoma and thyroid cancer cells.
48. Champa D, Russo MA, Liao X-H, Refetoff S, Ghossein RA, Di Cristofano A. Obatoclax

- overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. *Endocr Relat Cancer*. 21(5), 755–767 (2014).
- \* Characterized *BCL2A1* as an oncogene with antiapoptotic roles in cancers and showed that it conferred drug resistance to melanoma and thyroid cancer cells.
  - 49. Lionnard L, Duc P, Brennan MS, *et al.* TRIM17 and TRIM28 antagonistically regulate the ubiquitination and anti-apoptotic activity of BCL2A1. *Cell Death Differ*. 26(5), 902–917 (2019).
  - 50. Jenal M, Batliner J, Reddy VA, *et al.* The anti-apoptotic gene BCL2A1 is a novel transcriptional target of PU.1. *Leukemia*. 24(5), 1073–1076 (2010).
  - 51. Beer TM, Hotte SJ, Saad F, *et al.* Custirsen (OGX-011) combined with cabazitaxel and prednisone versus cabazitaxel and prednisone alone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel (AFFINITY): a randomised, open-label, international, ph. *Lancet Oncol*. 18(11), 1532–1542 (2017).
  - \* Showed that inhibition of molecules that promote cancer drug resistance, via ASOs, increased drug response and survival of CRPC patients in clinical trials.
  - 52. Bellmunt J, Eigel BJ, Senkus E, *et al.* Borealis-1: A randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. *Ann. Oncol*. 28(10), 2481–2488 (2017).
  - 53. Yu EY, Ellard S, Hotte SJ, *et al.* A randomized phase 2 study of a HSP27 targeting antisense, apatorsen with prednisone versus prednisone alone, in patients with metastatic castration resistant prostate cancer. *Invest. New Drugs*. 36(2), 278–287 (2018).
  - \* Showed that inhibition of molecules that promote cancer drug resistance, via ASOs, increased drug response and survival of CRPC patients in clinical trials.
  - 54. Pan Y, Zhang Y, Liu W, *et al.* LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. *Cell Death Dis*. 10(2) (2019).
  - 55. Si X, Zang R, Zhang E, *et al.* LncRNA H19 confers chemoresistance in ER $\alpha$ -positive breast cancer through epigenetic silencing of the pro-apoptotic gene BIK. *Oncotarget*. 7(49), 81452–81462 (2016).
  - 56. Fu Y, Wang W, Li X, *et al.* LncRNA H19 interacts with S-adenosylhomocysteine hydrolase to regulate LINE-1 Methylation in human lung-derived cells exposed to Benzo[a]pyrene. *Chemosphere*. 207, 84–90 (2018).
  - 57. Richards L. Prostate cancer: Cabazitaxel boosts post-docetaxel survival. *Nat. Rev. Urol*. 7(12), 645 (2010).

58. Chen X, Xie R, Gu P, *et al.* Long noncoding RNA LBCs inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2. .
59. Miao H, Wang L, Zhan H, *et al.* A long noncoding RNA distributed in both nucleus and cytoplasm operates in the PYCARD-regulated apoptosis by coordinating the epigenetic and translational regulation. *PLoS Genet.* 15(5), e1008144 (2019).
60. Zong L, Hattori N, Yasukawa Y, *et al.* LINC00162 confers sensitivity to 5-Aza-2'-deoxycytidine via modulation of an RNA splicing protein, HNRNPH1. *Oncogene.* 38(26), 5281–5293 (2019).
61. Vaughan EE, Dean DA. Intracellular trafficking of plasmids during transfection is mediated by microtubules. *Mol Ther.* 13(2), 422–428 (2006).
62. Van Gaal EVB, Oosting RS, Van Eijk R, *et al.* DNA nuclear targeting sequences for non-viral gene delivery. *Pharm. Res.* 28(7), 1707–1722 (2011).
63. Huang W, Su G, Huang X, *et al.* Long noncoding RNA PCAT6 inhibits colon cancer cell apoptosis by regulating anti-apoptotic protein ARC expression via EZH2. *Cell Cycle.* 18(1), 69–83 (2019).
64. Misawa A, Takayama KI, Fujimura T, Homma Y, Suzuki Y, Inoue S. Androgen-induced lncRNA POTEF-AS1 regulates apoptosis-related pathway to facilitate cell survival in prostate cancer cells. *Cancer Sci.* 108(3), 373–379 (2017).
65. Yu S, Wu C, Tan Q, Liu H. Long noncoding RNA H19 promotes chemotherapy resistance in choriocarcinoma cells. *J. Cell. Biochem.* 120(9), 15131–15144 (2019).
66. Chen S, Xia X. Long noncoding RNA NEAT1 suppresses sorafenib sensitivity of hepatocellular carcinoma cells via regulating miR-335–c-Met. *J. Cell. Physiol.* , 1–11 (2019).
67. Komura K, Jeong SH, Hinohara K, *et al.* Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression. *Proc. Natl. Acad. Sci. U. S. A.* 113(22), 6259–6264 (2016).
68. Martin SK, Banuelos CA, Sadar MD, Kyprianou N. N-terminal targeting of androgen receptor variant enhances response of castration resistant prostate cancer to taxane chemotherapy. *Mol. Oncol.* 9(3), 628–639 (2015).
69. Shiota M, Kashiwagi E, Yokomizo A, *et al.* Interaction between docetaxel resistance and castration resistance in prostate cancer: Implications of Twist1, YB-1, and androgen receptor. *Prostate.* 73(12), 1336–1344 (2013).
70. Vogler M. BCL2A1: The underdog in the BCL2 family. *Cell Death Differ.* 19(1), 67–74 (2012).



71. Ye Y, Shen A, Liu A. Long non-coding RNA H19 and cancer: A competing endogenous RNA. *Bull Cancer*. 106(12), 1152–1159 (2019).